CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-08-18). The draft was written by AI, the existence of all 1 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.7.
Verdict No. 2848 · Search date 2026-08-18 · Methodology v0.7

Oxycodone-, hydrocodone-, or codeine-acetaminophen combination analgesics,
does it really help with Superior two-hour analgesia versus ibuprofen-acetaminophen for acute extremity pain in the emergency department?

30-Second Summary
D
Evidence Grade D · 34 · Safety caution
Opioid combinations did not provide better two-hour acute extremity pain relief than ibuprofen-acetaminophen
The trial did not assess adverse events. Opioids can cause nausea, dizziness, sedation, and respiratory depression, and repeated exposure carries dependence and misuse risks, so dose and duration should be minimized.
What the
research shows
The grade is D. Among 411 analyzed patients, mean two-hour NRS pain reduction was 4.3 with ibuprofen-acetaminophen, 4.4 with oxycodone-acetaminophen, 3.5 with hydrocodone-acetaminophen, and 3.9 with codeine-acetaminophen. The overall four-group comparison was P=.053. The claim that opioid combinations provide greater relief was not supported.
What the
ads claim
Opioid combinations are a real prescribing issue in Korean emergency and pain practice. In the context of overprescribing and transition to longer use, a stronger-drug label should not be assumed to mean better two-hour analgesia.
*

Useful facts when choosing a product

  • Doses were ibuprofen 400 mg plus acetaminophen 1000 mg; oxycodone 5 mg plus 325 mg; hydrocodone 5 mg plus 300 mg; and codeine 30 mg plus 300 mg.
  • Rescue analgesia was given to 73/411, 17.8%, within two hours, with P=.42 across groups.
  • The trial did not assess adverse events, so it cannot compare group-specific nausea or dizziness rates.
Gap Measurement · Verdict 2848 · D 34
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Two Bronx emergency departments randomized 416 participants, 104 per group, and analyzed 411 after excluding five who had met a pre-randomization exclusion criterion. The primary analysis was a one-way analysis of variance across all four groups for two-hour NRS decline. After the overall P=.053 result, all pairwise differences used Bonferroni-adjusted 99.2% CIs. Ibuprofen-acetaminophen versus oxycodone was -0.1, 99.2% CI -1.0 to 0.8; versus hydrocodone 0.8, -0.2 to 1.7; and versus codeine 0.4, -0.6 to 1.3, calculated as the first drug's reduction minus the second's. Thus the maximum opioid advantage was 1.0, 0.2, and 0.6 points, each below the prespecified 1.3-point MCID. Evidence for no listed defect ① Allocation concealment: 'The randomized allocation schedule could only be accessed by the research pharmacist, who had no role in dispensing the medication.' ② Blinding: 'The pharmacist masked the analgesics by placing them into identical unmarked opaque capsules, which were packed with small amounts of lactose to equalize weight and then sealed.' ③ Analysis population and missing data: 'An intention-to-treat analysis was performed.' and 'Multiple imputation using chained equations was used to keep these patients in the intention-to-treat analysis.' ④ Prespecified primary endpoint: 'The primary outcome was the between-group difference in mean change in NRS pain score ... to 2 hours later.' - consistent with registration NCT02455518. An active-only control formally applied, but leaving moderate-to-severe acute pain untreated for two hours would be unethical, so it was not an avoidable limitation. Two hours matches the single-dose acute-analgesia question and was not counted as short follow-up.

02

Why this is classified as D (34)

A publicly funded, well-concealed double-blind trial precisely excluded opioid superiority as large as the prespecified MCID on a patient-centered endpoint, but no independent repeated trial addressed the same question, giving D with 34 points.

Counterpoint. This single-dose two-hour result does not answer longer-duration treatment, repeated dosing, discharge prescriptions, or patients unable to take NSAIDs.

Rejudgment record. Cross-check applied — The four-group primary test failed, and Bonferroni-adjusted pairwise intervals excluded opioid superiority as large as the prespecified MCID in a publicly funded double-blind trial

Scoring profile behind this grade
EndpointPPatient-reported treatment goal - the symptom is the goal
ReplicationR1Single confirmatory trial
IndependenceI2Decisive evidence is publicly or non-profit funded
Effect sizeE0Null
PrecisionC1The confidence interval excludes meaningful benefit

The scoring table and the verdict agree (D).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Superior two-hour analgesia from opioid-acetaminophen combinationsDThe overall P value was .053, and all pairwise comparisons excluded superiority as large as the prespecified MCID.
Equivalent safety of opioid combinations?This trial did not assess adverse events.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Study 1Two-emergency-department randomized double-blind four-group single-dose superiority trial103US NIH National Institute on Aging award 7K23AG033100-07; no author conflicts reportedBetween-group difference in mean change in 0-to-10 NRS pain from before dosing to two hoursReductions of 4.3 with ibuprofen-acetaminophen, 4.4 with oxycodone, 3.5 with hydrocodone, and 3.9 with codeine; overall P=.053; all pairwise 99.2% CIs excluded a 1.3-point superiority advantagePivotal publicly funded precise null single trial
§

Receipt — 1 References

All 1 cited sources were verified for existence at the original page (as of 2026-08-18).

Chang AK, Bijur PE, Esses D, Barnaby DP, Baer J. Effect of a Single Dose of Oral Opioid and Nonopioid Analgesics on Acute Extremity Pain in the Emergency Department: A Randomized Clinical Trial. JAMA. 2017;318(17):1661-1667. PMID: 29114833. DOI: 10.1001/jama.2017.16190.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-18 · Corrections: none

Cite this verdict

Opioid-Acetaminophen Combinations Are Not Superior to Ibuprofen-Acetaminophen for Acute Extremity Pain - No Benefit Evidence Grade D card
[Chamgap] Opioid-Acetaminophen Combinations Are Not Superior to Ibuprofen-Acetaminophen for Acute Extremity Pain - No Benefit — Evidence Grade D·34. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/general/opioid-acetaminophen-ibuprofen-acetaminophen-acute-extremity-pain/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.